FDA Issues Long-Awaited Draft Guidances on Internet and Social Media Advertising
- Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices; and
- Internet/Social Media Platforms with Character Space Limitations—Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices.
The first guidance offers recommendations on how prescription drug and device companies can correct inaccurate information about their products posted by third parties on internet and social media sites. The second guidance addresses how these same companies can discuss their products on internet platforms with space restrictions, including social media sites and paid search links on Google and Yahoo. Comments for both guidances are due within 90 days.
Today’s draft guidances address two issues of particular interest to Hogan Lovells clients – providing links to risk information within microblogs and correcting misinformation about products from third parties. Thus, we urge everyone to read these carefully.
Today’s draft guidances add to the social media draft guidance that the agency promulgated in January: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics, see our HL Regulatory blog post here. FDA has also indicated that its guidance agenda for 2014 includes guidance regarding the use of links in advertising and promotional labeling.
On 26 September 2016, a new EU-US collaboration between the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) was announced. This new collaboration is ...06 October 2016
On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...08 September 2016